Content area
Full Text
A 64-year-old man developed leucopenia during treatment with adalimumab. He started receiving adalimumab [route and dosage not stated] for psoriasis arthritis. His initial WBC count was 6200/mm3. After 3 administrations of adalimumab, his WBC count fell to 3500/mm3. His treatment with adalimumab was discontinued. His WBC count rose to 5000/mm3, after 4 weeks. He again received adalimumab. His treatment was repeatedly discontinued and resumed, depending up on the WBC count.